Previous Article | Next Article ![]()
Journal of Virology, November 2007, p. 12427-12438, Vol. 81, No. 22
0022-538X/07/$08.00+0 doi:10.1128/JVI.01105-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

,
Emilio Yángüez,1,
Nahum Sonenberg,2 and
Amelia Nieto1*
Centro Nacional de Biotecnología, CSIC Darwin 3, Cantoblanco 28049, Madrid, Spain,1 Department of Biochemistry, and McGill Cancer Center, McGill University, Montreal, Quebec H3G 1Y6, Canada2
Received 22 May 2007/ Accepted 30 August 2007
|
|
|---|
|
|
|---|
The influenza virus RNA polymerase is a complex composed of three subunits: PA, PB1, and PB2. The synthesis of capped and polyadenylated viral mRNAs is primed by short capped oligonucleotides of around 10 to 12 nucleotides, which are scavenged from host cell nuclear mRNAs by viral polymerase endonuclease activity (46). The PB2 subunit is responsible for the binding of the cap structures (4), while it is thought that the endonucleolytic activity required for the "cap-snatching" process lies in the PB1 subunit (36). Influenza virus mRNAs therefore contain host cell-derived sequences at their 5' ends followed by a highly conserved sequence that is common to all viral genes. It has been reported that the influenza virus polymerase complex binds to this common sequence in vitro (51). This association increases the cap-binding activity of the polymerase complex and enhances its binding to the capped viral mRNAs, protecting them from the cap-snatching process (51). The 3' end of viral messengers is polyadenylated by a reiterative copy of a U5-7 track present near the 5' end of the viral RNA (38). Consequently, although different pathways synthesize cellular and viral mRNAs, both types of mRNAs are structurally similar.
Influenza virus efficiently shuts off host cell protein synthesis (21). Upon infection of susceptible cells, initiation and elongation steps of translation of cellular mRNAs are inhibited (31). This translational control is accompanied by a selective translation of viral mRNAs, with the sequences within the 5' untranslated regions (UTRs) playing a critical role (21). The NS1 viral protein is important for the selective translation of viral messengers, especially for the late ones, by increasing their rate of initiation (10, 14, 31, 43). This process is mediated by its functional interaction with the 5'-terminal conserved sequences of viral mRNAs (10, 43). We have identified two cellular targets of NS1 that support its role in protein translation: the eIF4GI subunit of eIF4F (1) and poly(A) binding protein 1 (PABP1) (5). However, there are NS1 mutant viruses (point mutations or partial or total deletions of the NS1 protein) that present alterations in protein synthesis but that are still capable of inducing cellular shutoff and performing selective translation of their own mRNAs (17, 19, 26, 48). These data suggest that other viral factors should be involved in the translation of viral mRNAs. Influenza virus infection alters the translation initiation eIF4F complex: the cap-binding protein eIF4E becomes underphosphorylated, and the factor eIF4GI becomes hyperphosphorylated (18). On the other hand, influenza virus infection cannot proceed in poliovirus-infected cells, where the eIF4G factor is cleaved (20). This suggests that viral mRNA translation requires full-length eIF4G and therefore does not proceed by an internal cap-independent translation initiation pathway. To elucidate the mechanisms involved in the selective translation of viral messengers during infection, we examined whether viral polymerase, as a cap-binding protein complex, functions as the cap-binding factor for viral mRNA translation, allowing functional independence from the cellular cap-binding protein eIF4E.
|
|
|---|
UTR, pCMVPB1
UTR, and pCMVPB2
UTR that express PA, PB1, and PB2 polymerase subunits but that do not contain the 5' and 3' influenza virus UTR sequences were used and kindly provided by P. Resa. HEK293T, HeLa, and A549 cell lines were used throughout. Vero and ST-hAPN cells were used to amplify recombinant influenza virus lacking NS1 (48) and human coronavirus HCoV-229E (34), respectively. Monoclonal antibody against green fluorescent protein (GFP) and complete protease and RNase (human placenta RNAse inhibitor) inhibitors were obtained from Roche. Rapamycin was obtained from Calbiochem. Construction of plasmids. For the construction of 4E-BP1-expressing plasmids, human 4E-BP1 cDNA was used as a template for PCR mutagenesis to mutate T37, T46, S65, and T70 to alanine. Wild-type or mutated sequences were inserted in frame into vector pcDNA3-3HA (which contains an N-terminal fusion with a tag comprising three hemagglutinin [HA] epitopes).
The eIF4E-silencing plasmid pSUPERretroNeoGFP-4E (pSUPER-GFP-4E) expressing the short hairpin RNA corresponding to positions 447 to 465 of eIF4E mRNA was generated according to the manufacturer's instructions (Oligoengine). This short hairpin showed no homology to other gene sequences when using BLAST. Control plasmid pSUPERretroNeo-GFP-TM (a gift of A. Rodriguez) expresses a nonsilencing short hairpin RNA derived from a transcript of the bacterium Thermotoga maritima and does not target any known mammalian gene (the targeted sequence is AATTCTCCGAACGTGTCACGT).
Transfection and virus infection. All infections were carried out at a multiplicity of infection of 5 to 10 PFU/cell. Where needed, HEK293T or HeLa cells were previously transfected by the calcium-phosphate method (52) or using FUGENE HD reagent (Roche Applied Science), respectively. At different times postinfection, the cells were used for studies using sucrose gradient separation, immunofluorescence, metabolic labeling, or binding to m7GTP resins (cap resins). In eIF4E gene silencing experiments, when transfection efficiency was lower than 70%, the cells were separated using GFP fluorescence by a MoFlo cell sorter (DAKO Cytomation). Viral RNPs were reconstituted as previously described (44).
Western blotting.
Western blotting was done as described previously (1). The following primary antibodies were used: a mixture of four rabbit polyclonal antibodies (1:8,000 each) was used for translation initiation factor eIF4GI (1), a monoclonal antibody from Transduction Laboratories (1:2,000) was used for eIF4E, monoclonal antibodies 2 and 14 (1:20 each) (28) were used for PA, a rat polyclonal antibody (1:1,000) (a gift of J. Ortín) was used for PB1, monoclonal antibodies 8 and 28 (1:100 each) (28) were used for PB2, a rat polyclonal antibody (1:1,000) (a gift of J. Ortín) was used for the NP protein, and a rabbit polyclonal antibody (1:10,000) (1) was used for the NS1 protein. For ß-actin, a mouse monoclonal antibody (1:50,000) from Sigma was used; for 4E-BP1, a rabbit polyclonal antibody (1:1,000) from Cell Signaling Technology was used; for GAPDH (glyceraldehyde-3-phosphate dehydrogenase), a rabbit polyclonal antibody (1:5,000) was used; for RNA polymerase II, a mouse monoclonal antibody (1:500) from Covance was used; for HA, a mouse monoclonal antibody (1:1,000) from Abcam was used; and for total eIF2
, a rabbit polyclonal antibody from Santa Cruz (1:2,000) was used, and for its phosphorylated form (eIF2
[pS52]), a rabbit polyclonal antibody from Biosource (1:200) was used.
Immunofluorescence. HEK293T or HeLa cells were fixed, permeabilized, and incubated with the following primary antibodies: anti-NP (1:2,000), anti-coronavirus S protein (1:20) (a gift of L. Enjuanes), anti-GFP (1:1,000), and anti-HA (1:1,000 or 1:500 when using monoclonal or polyclonal antibodies, respectively). Microscopy was performed with a Leica DMRX epifluorescence microscope or with a Bio-Rad Radiance 2100 confocal laser scanning system on a Zeiss Axiovert 200 microscope.
Analysis of viral proteins associated with translation initiation complexes. HEK293T cells were mock or influenza virus infected, and at 7 h postinfection (hpi), the cells were collected and lysed in buffer A (150 mM NaCl, 1.5 mM MgCl2, 10 mM Tris-HCl [pH 8.5], 0.2% Igepal) with protease (complete) and phosphatase (5 mM Na3VO4, 5 mM ß-glycerophosphate, 5 mM sodium molibdate) inhibitors plus the RNase inhibitor human placenta RNAse inhibitor (1:1,000). The lysate was centrifuged at 10,000 x g, and the supernatant was loaded into a 7 to 47% sucrose gradient and centrifuged for 14 h at 24,000 rpm at 4°C in a SW41Ti (Beckman) rotor. Fractions were collected from the top of the gradient and resuspended in Laemmli sample buffer or used for immunoprecipitation studies. For coimmunoprecipitation, the corresponding fractions were extensively dialyzed in buffer A without detergent and incubated with specific anti-eIF4GI antibody or preimmune serum as reported previously (1). The immunocomplexes were washed five times with buffer A and analyzed by sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and Western blotting.
To analyze the association of influenza virus polymerase subunits with translation initiation complexes and to study the contribution of viral mRNA to this association, p100 plates of HEK293T cells were transfected with 3 µg of plasmids pCMVPB1
UTR and pCMVPB2
UTR and 0.6 µg of plasmid pCMVPA
UTR without the 5' and 3' influenza virus UTR sequences. Sixteen hours later, cytosolic extracts were prepared in buffer A containing proteases, phosphatases, and RNase inhibitors; after centrifugation at 10,000 x g, the supernatants were collected and used for coimmunoprecipitation studies as described above.
Cap-binding assays. HEK293T cells were left untransfected or were transfected with empty plasmid or plasmids expressing wild-type or mutated 4E-BP1 proteins. Next, they were mock or influenza virus infected. At different times, the cells were collected and lysed in buffer A with proteases, phosphatases, and RNase inhibitors as described above. The lysates were centrifuged at 10,000 x g, and the supernatants were incubated with Sepharose-m7GTP (Amersham) or Sepharose-4B (Sigma), as a negative control, overnight at 4°C. The resins were washed five times with buffer A, resuspended in Laemmli sample buffer, and analyzed by SDS-polyacrylamide gel electrophoresis and Western blotting.
Metabolic labeling. For continuous labeling, HEK293T cells that were mock infected or infected with the VIC strain of influenza virus were incubated with medium containing 30 µCi/ml of [35S]Met-Cys during the last 4 to 5 h of infection. For pulse experiments, 100 µCi/ml of [35S]Met-Cys was added during 30 min or 1 h at the indicated times.
|
|
|---|
![]() View larger version (50K): [in a new window] |
FIG. 1. Separation of influenza virus polymerase from viral RNPs. HEK293T cells were mock or influenza virus infected for 7 h with the VIC strain at 5 to 10 PFU/cell. (A) Subcellular fractionation. Nuclear (N) and cytosolic (C) fractions from total extracts (T. Ext.) were separated and analyzed by Western blotting with specific antibodies against RNA polymerase II (RNAP II) or GAPDH. (B) Separation of viral polymerase subunits from viral RNPs. HEK293T cells were labeled in vivo during the last 4 h of infection (Promix; Amersham). Next, the cells were collected and processed as described in Materials and Methods, and the labeled proteins were analyzed by autoradiography ([35S]Met-Cys). Samples of the same fractions were analyzed by Western blotting with specific antibodies against the indicated proteins. (C) Viral RNP expressing NS1 was reconstituted in vivo and processed as described above (B). The corresponding proteins were analyzed by Western blotting.
|
![]() View larger version (37K): [in a new window] |
FIG. 2. Influenza virus polymerase subunits associate with translation initiation complexes. (A) Cytosolic extracts from mock-infected or VIC-infected HEK293T cells were applied to sucrose gradients and processed as described in Materials and Methods. Samples were used for immunoprecipitation studies (Ip) using specific antibodies against the eIF4GI protein (I) or the preimmune serum (C). (B) HEK293T cells were infected with the delNS1 strain, and cytosolic extracts were immunoprecipitated as described above (A) to analyze the associated proteins by Western blotting. (C) HEK293T cells were untransfected (MOCK) or cotransfected with plasmids expressing PB1, PB2, and PA (PB1+PB2+PA), and cytosolic extracts were prepared and immunoprecipitated with eIF4GI antiserum as described above. The polymerase proteins associated with eIF4GI were analyzed by Western blotting.
|
To further characterize the association of viral polymerase with translation initiation complexes outside the context of viral infection, we coexpressed PB1, PB2, and PA polymerase subunits in HEK293T cells and performed coimmunoprecipitation assays. Moreover, to study the contribution of viral mRNAs to the association, we used plasmids that express the polymerase subunits but that do not contain the 5' and 3' UTR sequences of influenza virus mRNAs, and therefore, viral mRNAs were not present in the assay. The results are presented in Fig. 2C. The three polymerase subunits were found in the immunocomplexes together with the eIF4GI protein, although the efficiency of coimmunoprecipitation was lower than that obtained when influenza virus-infected cells were used. This could be due to the fact that not all the coexpressed polymerase subunits are forming polymerase complexes, since an important fraction remains as free subunits. Nevertheless, these results indicate that PB1, PB2, and PA coimmunoprecipitate with eIF4GI in the absence of viral mRNAs, corroborating the finding that polymerase subunits interact with translation initiation complexes and indicating that viral mRNA is not required for this association.
Translation of influenza virus mRNAs occurs under conditions of functional impairment of cellular cap-binding protein eIF4E. The above-described results raised the possibility that viral polymerase could replace the cellular cap-binding protein eIF4E. This replacement would allow the translation of viral mRNAs without the contribution of this cellular factor. This possibility was examined using three different approaches.
(i) Translation of influenza virus mRNAs is rapamycin insensitive. The mTOR protein kinase regulates protein synthesis through the phosphorylation and inactivation of the repressor of cap-dependent translation, the 4E-binding protein (4E-BP), and through the phosphorylation and activation of S6 kinase. Phosphorylation of 4E-BP is inhibited in vivo by the drug rapamycin, leading to a reduction in cap-dependent translation (reviewed in reference 24). HeLa cells were preincubated with or without rapamycin at a concentration of 20 ng/ml in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum for 12 h. To control the effectiveness of the drug, we analyzed the degree of phosphorylation of 4E-BP1 and observed bands with higher electrophoretic mobility corresponding to more dephosphorylated isoforms upon rapamycin treatment (Fig. 3A). For loading controls in Western blots, we analyzed the ß-actin protein, whose half-life is greater than 100 h (7). No variations were found in its accumulation levels after the drug treatment. Treated and untreated cells were subsequently infected with influenza virus in the presence or absence of the drug. At different hpi, the cells were metabolically labeled with [35S]Met-Cys for 30 min, and the synthesized proteins were analyzed by SDS-polyacrylamide denaturing gels (Fig. 3B). In agreement with previous results (3, 39), rapamycin led to a reduction in global protein synthesis in mock-infected cells of approximately 50% (measured by label quantitation). In contrast, efficient viral protein translation was observed under these conditions. To estimate the effect of rapamycin on the protein synthesis of defined proteins, we selected an abundant cellular protein and the viral polymerase subunits to perform quantitative analysis. The results (Fig. 3C) show that the synthesis of the cellular protein in cells treated with rapamycin is around 30% of the synthesis in control cells. In contrast, the synthesis of viral polymerase is unaffected under these conditions, indicating that viral translation is insensitive to drug treatment.
![]() View larger version (60K): [in a new window] |
FIG. 3. Influenza virus infection progresses efficiently in rapamycin-treated cells. (A) HeLa cells treated with (+) or without (–) rapamycin for 12 h were subjected to Western blotting against 4E-BP1 or actin. (B) HeLa cells treated with (+) or without (–) rapamycin for 12 h were mock infected (MOCK) or infected with the VIC strain, maintaining the rapamycin condition. At the indicated hpi, the cells were metabolically labeled, and the proteins were analyzed by SDS-polyacrylamide gels and autoradiography. (C) Quantitation of the incorporated label in specific cellular and viral proteins (marked with asterisks) from B. (D) A549 cells treated with (+) or without (–) rapamycin were processed as indicated above (B).
|
(ii) Translation of influenza virus mRNAs is not affected in eIF4E-silenced cells.
The next approach was the use of gene-silencing experiments using RNA interference. With this aim, HEK293T cells were transfected with a control silencing plasmid (pSUPER-GFP-TM) or with a plasmid specific for eIF4E silencing (pSUPER-GFP-4E). To avoid the contribution of eIF4E from untransfected cells, they were sorted 12 h after transfection by using GFP fluorescence. Selected cells were plated again and infected with influenza virus 36 h posttransfection. At the indicated hpi, aliquots were used for Western blotting, metabolic labeling with [35S]Met-Cys, and immunofluorescence studies. As can be seen in Fig. 4A, the eIF4E-silencing plasmid efficiently decreased the accumulation levels of the eIF4E protein compared with the control plasmid. The recognition of the interfering double-stranded RNA by oligoadenylate synthetase (2',5'-oligoadenylate synthetase) and PKR pathways of the innate cellular defense system could result in nonspecific translation inhibition (12) due to the general RNA degradation or phosphorylation of the eIF2
factor, respectively. The integrity of the cellular RNA was evaluated by ethidium bromide staining of total RNA isolated from transfected HEK293T cells, and no degradation was observed under any experimental condition (data not shown). On the other hand, the down-regulation of eIF4E did not increase the degree of phosphorylation of the eIF2
protein (Fig. 4A). Similar accumulation levels of the eIF2
protein were obtained in control and silenced cells using an antibody that recognizes total levels of the eIF2
protein (Fig. 4A). These results indicate that the activation of neither PKR nor oligoadenylate synthetase pathways takes place in our gene-silencing conditions. Total protein synthesis upon eIF4E silencing is shown in Fig. 4A. As a loading control, we used the accumulation of total eIF2
. Quantitation analysis showed that transfection with plasmid pSUPER-GFP-4E significantly inhibited the translation of cellular mRNAs, presenting a 30 to 35% reduction compared with the translational rate of control cells. This inhibition is in agreement with data from previous reports analyzing either total cellular protein synthesis (13) or the translation of defined cellular mRNAs (42). In contrast, the synthesis of viral proteins (Pol, NP, NS1, and M1) was unaffected. To estimate the effect of eIF4E silencing on the protein synthesis of defined proteins, we selected cellular and viral (HA and neuraminidase) proteins to perform a quantitative analysis. The results in Fig. 4B show that the synthesis level of the cellular protein in eIF4E-silenced cells is around 50% of the synthesis in control cells, whereas the synthesis of viral proteins is unaffected, indicating that viral translation occurs normally upon eIF4E silencing. Immunofluorescence studies were also carried out, and we observed that influenza virus infection takes place in eIF4E-silenced cells with normal kinetics of viral RNP production and export (data not shown).
![]() View larger version (63K): [in a new window] |
FIG. 4. Gene silencing of the eIF4E factor does not affect influenza virus protein synthesis but inhibits cellular protein translation. HEK293T cells were transfected with control pSUPER-GFP-TM (TM) or pSUPER-GFP-4E (4E) plasmids. Twelve hours after transfection, the cells were selected by cell sorting using the GFP fluorescence and plated again. Thirty six hours posttransfection, cells were infected with influenza virus. (A) At the indicated hpi, aliquots were taken and used for Western blotting against the indicated proteins and metabolic labeling with [35S]Met-Cys. (B) Quantitation of the incorporated label in specific cellular and viral proteins (marked with asterisks) from the [35S]Met-Cys panel.
|
![]() View larger version (60K): [in a new window] |
FIG. 5. Overexpression of HA-4E-BP1 proteins does not affect influenza virus infection in HEK293T cells. (A) HEK293T cells were untransfected (M) or transfected with plasmids expressing HA-tagged wild-type 4E-BP1 (WT) or nonphosphorylatable 4E-BP1 (4A) protein. At 36 h posttransfection, total cell extracts (T.ext.) were used to study eIF4GI, eIF4E, and HA-4E-BP1 (HA) retention either to cap resins or to Sepharose-4B control resins (ctrl-resin) by Western blotting. Quantitation of eIF4GI protein retained on the cap resins is shown on the right. (B) HEK293T cells were transfected with plasmid pcDNA3-HA-4E-BP1 wt or pcDNA3-HA-4E-BP1 4A, and 36 h posttransfection, the cells were mock or influenza virus infected with either the VIC (top) or delNS1 (bottom) strain. At the indicated hpi, cells were fixed and used for immunofluorescence using antibodies against HA to monitor plasmid transfection and NP protein to monitor influenza virus infection. Asterisks indicate transfected and infected cells. DAPI, 4',6'-diamidino-2-phenylindole.
|
![]() View larger version (24K): [in a new window] |
FIG. 6. Overexpression of underphosphorylated 4E-BP1 protein impairs human coronavirus infection. HeLa cells were transfected with plasmid pcDNA3-HA-4E-BP1 wt (A) or pcDNA3-HA-4E-BP1 4A (B), and 36 h posttransfection, the cells were mock or coronavirus infected. At the indicated hpi, cells were used for immunofluorescence using antibodies against HA to monitor plasmid transfection and S protein to monitor coronavirus infection. Asterisks indicate transfected and infected cells. # indicates cells that were transfected but uninfected. DAPI, 4',6'-diamidino-2-phenylindole. (C) Quantitation of the efficiency of infection in untransfected cells (–) and in pcDNA3-HA-4E-BP1 wt (WT)- or pcDNA3-HA-4E-BP1 4A (4A)-transfected cells subsequently infected with influenza virus (data not shown) or human coronavirus HCoV-229E.
|
![]() View larger version (56K): [in a new window] |
FIG. 7. Influenza virus infection enhances the recruitment of eIF4GI to cap resins. (A) Cytosolic extracts (T. Ext.) of mock-infected (M) or influenza virus-infected (5 and 8 hpi) HEK293T cells were applied to m7GTP-Sepharose resins (cap resins) or to Sepharose-4B control resins (ctrl-resins), and the indicated proteins were analyzed by Western blotting. (B) HEK293T cells were transfected with plasmid pcDNA3-HA (HA), pcDNA3-HA-4E-BP1 wt (WT), or pcDNA3-HA-4E-BP1 4A (4A), and 36 h posttransfection, the cells were mock (M) or influenza virus infected (5 hpi). Cytosolic extracts (T. Ext.) were prepared and applied to m7GTP-Sepharose resins (cap-resin). Retention of the indicated proteins was evaluated by Western blot analysis, and quantitation is shown on the right (means and standard deviations). (C) Experiment similar to that performed in B but using recombinant delNS1 influenza virus. On the right side, the quantitation of the eIF4GI protein retained in the cap resins as described in the text is shown.
|
|
|
|---|
Different viral mechanisms are used to efficiently translate viral mRNAs. A wide range of picornaviruses have mRNAs in which initiation occurs downstream of the 5' end, on internal ribosome entry sites, allowing cap-independent initiation. These picornaviruses encode a protease that cleaves the eIF4G protein into two polypeptides and separates the eIF4E-binding domain from the eIF3-binding domain. This causes the uncoupling of cellular mRNA recognition (via the cap structure and the eIF4E protein) and small ribosomal subunit recruitment (via ribosome-bound eIF3), thereby impairing cap-dependent initiation (for reviews, see references 6 and 50).
Among the viruses whose mRNAs possess a cap structure, a well-understood example is the case of rotavirus (a double-stranded RNA virus), which encodes mRNAs that are capped but not polyadenylated. The viral nonstructural protein NSP3 binds to eIF4G and the 3' end of rotavirus mRNAs, disrupting the eIF4G-PABP1 interaction that stimulates initiation and thereby inhibits cellular mRNA translation (45). Surprisingly, the list of viruses whose mRNAs hold a 5' cap structure and show an unexpected low dependence of the functionally active eIF4E factor is growing quickly. Infection with adenovirus provokes robust eIF4E dephosphorylation, which is consistent with its inhibition of host protein synthesis. This virus encodes a 100-kDa protein that binds to eIF4G and displaces the eIF4G-Mnk1 interaction, thus eliminating the ability to phosphorylate eIF4E (9). Adenovirus promotes selective translation through a cap-dependent translation mechanism known as ribosome shunting. In this case, there is a loading of 40S ribosome subunits onto the mRNA and then a translocation of 40S ribosome subunits to the initiation codon (50, 53). Infection with vesicular stomatitis virus produces the dephosphorylation of the eIF4E and 4E-BP1 proteins, which results in a reduced eIF4E-eIF4G association (8). An alternative translation mechanism has not yet been described for this virus. Recently, it has been reported that dengue virus translation takes place under conditions of limited amounts of eIF4E where cap-dependent translation is compromised (13). In this case, it has been proposed that a decrease in the concentration of eIF4E prompts a reorganization of the viral RNP complexes bridging the 5' and 3' UTRs, allowing the recruitment of factors such as eIF4G and bypassing the requirement for the eIF4E factor (13).
Translation of influenza virus mRNAs. Translation of cellular mRNAs is strongly inhibited in influenza virus-infected cells. Some of the viral activities preclude the translation of de novo-synthesized cellular mRNAs. Thus, infection decreases the synthesis of cellular mRNAs, probably as a consequence of virally induced cap-snatching activity, and inhibits the nucleocytoplasmic transport of cellular mRNAs (32). Later in the infection, there is cytoplasmic degradation of cellular mRNAs (2, 29). Additionally, the virus has developed mechanisms to discriminate and selectively translate its 5'-capped and 3'-polyadenylated mRNAs among previously accumulated cellular mRNAs. As mentioned previously, the NS1 protein has an important role in the efficient translation of late viral mRNAs. However, in view of the phenotypes exhibited by several NS1 mutant viruses, other viral mechanisms need to operate to discriminate and efficiently translate viral mRNAs.
The fact that influenza virus infection cannot proceed in poliovirus-infected cells where the eIF4G initiation factor is cleaved (20) has traditionally led to the concept that influenza virus translation initiation occurs using the full eIF4F complex (eIF4E, eIF4G, and eIF4A) bound to capped viral messengers. Since viral polymerase binds to cap structures, we have considered that this association could block eIF4E accessibility to the cap. Here, we provide data indicating that viral translation occurs under various conditions of impairment of functional eIF4E such as rapamycin treatment, eIF4E gene silencing, and overexpression of constitutively underphosphorylated 4E-BP1. Additional data support the independence of viral mRNA translation of a fully active eIF4E factor. First, coinfection of influenza virus and adenovirus can simultaneously occur despite the strong dephosphorylation of eIF4E that causes adenovirus infection. Moreover, influenza virus infection also produces eIF4E dephosphorylation (18, 30). In line with the role of eIF4E dephosphorylation, adenovirus infection promotes the inhibition of host protein synthesis. Phosphorylation of eIF4E strongly correlates with the rate of translation in many systems, although its reduced phosphorylation does not affect the rate of translation in certain situations (49). Second, the expression of the antiviral molecule ISG15 and protein modification by ISG15 (ISGylation) are strongly activated by interferon and viral infection. It has been reported that as early as 3 days after infection, influenza virus-infected mice express large amounts of both free ISG15 and ISG15 conjugates in the lung (35). Very recently, it has been shown that 4EHP is modified by ISG15 and ISGylated (41). 4EHP is an mRNA 5' cap-binding protein expressed ubiquitously and acts as a translation suppressor of cap-dependent translation by competing with eIF4E for binding to the cap structure. The ISGylation of 4EHP drastically increases its cap-binding activity, suggesting that 4EHP may play an important role in the regulation of cap-dependent translation (41). These data indicate that influenza virus mRNAs would be translated even under conditions of high competition of eIF4E binding to cap structures due to ISGylation of the 4EHP protein.
We have shown that viral polymerase binds to translation initiation complexes (Fig. 2) and that influenza virus infection triggers the eIF4G association with cap structures (Fig. 7). Collectively, these results support a model in which influenza virus polymerase, bound to the viral 5' UTR common sequence, would remain associated with the capped 5' end of the viral mRNAs, avoiding the replacement by eIF4E and recruiting translation initiation complexes. In this context, it should be mentioned that m7GTP is a 200-fold-less-potent cap-binding inhibitor with influenza virus polymerase than with eIF4E factor (27), suggesting that viral polymerase binds to cap structures with greater affinity than eIF4E does. Although viral polymerase associates with eIF4GI-containing complexes, the direct partner of the viral polymerase among the translation initiation factors still remains unknown, and we are conducting experiments to elucidate the possible role of eIF4GI in this association. In addition, the interaction of NS1 with the translation initiation factors eIF4GI and PABP1 could help the formation of a "closed loop" between the 5' and 3' ends of the viral mRNA. Thus, both activities would cooperate actively to recruit translation initiation complexes and would enhance the efficiency of viral mRNA translation. At the initial step of infection, virion RNPs are transported into the nucleus, where they start viral transcription and replication. Viral mRNAs from primary transcription are then translated to generate new polymerase subunits and NP protein to perform influenza virus genome amplification. Previous studies have shown that the viral polymerase complex not associated in viral RNPs can be detected in the cytoplasm of infected cells at approximately 2.5 to 3.5 hpi (11). Thus, it is conceivable that translation at very early times postinfection takes place without the contribution of viral proteins, and as the infection proceeds and the eIF4E factor becomes dephosphorylated, the viral polymerase localized in the cytoplasm helps to recruit translation initiation complexes to viral mRNAs. This proposal is in agreement with the partial impairment of viral protein synthesis observed at early times postinfection in influenza virus-infected cells treated with rapamycin (Fig. 3). Further characterization of the role of polymerase in viral translation could facilitate an understanding of the underlying mechanisms involved in the preferential translation of viral mRNAs during influenza virus infection.
Concluding remarks. Unlike other alternative viral translation mechanisms that elude cap utilization, here, we propose an alternative cap-dependent way to initiate influenza virus mRNA translation. The results presented showing normal progression of influenza virus infection during functional impairment of cap-binding eIF4E factor are in agreement with a growing list of reports pointing out the reduced dependence of the cellular cap-binding factor for viral cap mRNA translation exerted by different viruses with 5' cap structures (adenovirus, vesicular stomatitis virus, and dengue virus). They also appear to indicate that this mechanism is more widespread than previously thought and could be a system developed by certain viruses to evade the requirement of a fully active cap initiation complex, contributing to the repression of host cell mRNA translation.
This work was supported by Ministerio de Educación y Ciencia (grants BMC2002-01141 and BFU2005-02834).
Published ahead of print on 12 September 2007. ![]()
I.B. and E.Y. contributed equally to this work. ![]()
Present address: Centro de Investigaciones Biológicas, CSIC Ramiro de Maeztu 9, 28040 Madrid, Spain. ![]()
|
|
|---|
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»